Publication | Open Access

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Tumor Immune MicroenvironmentCancer ImmunosurveillanceMedicineImmunologyTumor ImmunityT790m StatusBronchial NeoplasmImmune Checkpoint InhibitorNivolumab EfficacyImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentLung Cancer